EGFR and p185HER-2 in Non-Small-Cell Lung Cancer
Author Information
Author(s): P Pfeiffer, PP Clausen, K Andersen, C Rose
Primary Institution: Odense University Hospital, Denmark
Hypothesis
Are EGFR and p185HER-2 of prognostic value in patients operated on for NSCLC?
Conclusion
The study found that overexpression of EGFR and p185HER-2 is not prognostic in untreated patients with NSCLC.
Supporting Evidence
- 55% of tumors showed high expression of EGFR.
- 26% of tumors showed high expression of p185HER-2.
- Expression of EGFR was higher in squamous cell carcinomas.
- Expression of p185HER-2 was higher in adenocarcinomas.
- Neither receptor expression correlated with age, stage, or prognosis.
Takeaway
This study looked at two proteins in lung cancer patients to see if they could predict how well patients would do, but they found that these proteins didn't help with predictions.
Methodology
Immunohistochemical analysis of EGFR and p185HER-2 expression in cryosections from 186 patients with NSCLC.
Potential Biases
Potential selection bias due to the non-homogeneous population and small sample size in some studies.
Limitations
The study was limited by the lack of adjuvant therapy in most patients and potential selection bias.
Participant Demographics
The cohort included 131 men and 55 women with a median age of 61 years.
Want to read the original?
Access the complete publication on the publisher's website